Health and Healthcare
Another Stent Failure For Boston Scientific (BSX)
Published:
Last Updated:
Investors have another reason to bail out of Boston Scientific (BSX). It has been in a battle with the medical research community for over a year fighting the perception that its drug-coated stents may be unsafe.
Comments about the potential danger of stents has sharply cut their use for treatment of cardiovascular disease.
The latest research on stent use compared to open heart surgery indicates that stents are relatively less effective. According to Reuters, "Despite the advent of drug-eluting stents, surgery comes out a winner," Douglas Weaver, president of the American College of Cardiology.
If the study results had fallen the other way, BSX might have hoped for a pick-up in sales of one of its most important products.
No such luck. Shares in Boston Scientific trade at $13, down from $44 a little over four years ago.
Douglas A. McIntyre
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
